EVIDENCE PROFILE / PUBLISHED
NAD+
NAD+ is a nucleotide-derived redox coenzyme, not a peptide. Direct NAD+, precursors, and related vitamin forms are not interchangeable. A 2025 single-centre randomized study evaluated a short intravenous course in ischemic cardiomyopathy; a later retrospective commercial-setting pilot assessed tolerability. Neither establishes broad wellness or longevity benefit.
Evidence at a glance
- Human
- LimitedOne single-centre randomized study and one retrospective pilot.
- Animal/cell
- Not rated
- Approved medicine
- Not rated
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. It participates in redox reactions, energy metabolism, DNA-repair signaling, and enzyme systems including sirtuins and PARPs.
Identity
NAD+ is a nucleotide-derived redox coenzyme, not a peptide. Direct NAD+, precursors, and related vitamin forms are not interchangeable.
Biological mechanism or research interest
It participates in redox reactions, energy metabolism, DNA-repair signaling, and enzyme systems including sirtuins and PARPs.
Verified approved human uses
The reviewed human studies evaluated investigational direct NAD+ administration; they do not establish an approved use for the catalogue material.
Investigational human evidence
A 2025 single-centre randomized study evaluated a short intravenous course in ischemic cardiomyopathy; a later retrospective commercial-setting pilot assessed tolerability. Neither establishes broad wellness or longevity benefit.
Popular claims versus demonstrated findings
Energy, anti-aging, detoxification, and addiction-treatment claims are broader than demonstrated findings for direct NAD+ administration.
Human versus animal or cell evidence
Cellular necessity and animal bioenergetic findings do not establish benefit from an exogenous 500 mg material in people.
Limitations and known risks
The retrospective pilot recorded gastrointestinal symptoms, increased heart rate, and chest pressure during NAD+ infusions. Product quality, interactions, and long-term outcomes remain incompletely characterized.
